2005 issue 3


Volume 21, issue 3


Rasagiline - a new drug in the treatment of idiopathic Parkinson, s disease

Andrzej Friedman1, Monika Nojszewska1
1. Katedra i Klinika Neurologii Akademii Medycznej w Warszawie
Farmakoterapia w Psychiatrii i Neurologii, 2005, 3, 195-207
Keywords: Rasagiline, Parkinson's disease, monotherapy, adjuvant therapy


Rasagiline is a new, second generation drug with a potent, selective irreversible monoamine oxidase type B (MAO-B) inhibitor activity. In double-blind placebo controlled clinical trials its efficacy in the treatment for Parkinson's disease was established. Rasagiline as monotherapy improves motor symptoms of PD and additionally significantly decreases the 'off' time among patients with levodopa-induced motor fluctuations. Rasagiline is indicated for the treatment of idiopathic Parkinson's disease as monotherapy in early stages of the disease as well as adjuvant therapy with levodopa in advanced stages of PD.